SK Bio Pushes FDA Approval for Cenobamate in Seizures
Taking New Strides in Epilepsy Treatment Today, we’ve got SK Biopharmaceuticals banging on the FDA’s door with a pile of paperwork. They’re pushing for the green light on cenobamate to tackle primary generalized tonic-clonic (PGTC) seizures, plus expand its use to pediatric patients with the focal-onset seizure condition. Now, if you think it sounds like a big...
Continue Reading